Mar 16, 2022 / 02:15PM GMT
Balaji V. Prasad - Barclays Bank PLC, Research Division - Director
Good morning, everyone. My name is Balaji Prasad. I lead the Specialty Pharmaceuticals coverage for Barclays. Continuing on day 2 of our spec pharma track, I'm delighted to have the management team of Pacira with us. So from Pacira, we have Dave Stack, Chairman and CEO; and Charles Reinhart, CFO.
Dave and Charlie, thank you for taking your time and joining us today.
David M. Stack - Pacira BioSciences, Inc. - Chairman & CEO
Thank you for the opportunity.
Questions and Answers:
Balaji V. Prasad - Barclays Bank PLC, Research Division - DirectorFantastic. So I think as we look now with the updates that you had recently, and you also provided the Feb monthly sales. The question that I have been getting in the past few weeks since the Q4 call is really about ZILRETTA. I think there still seems to be significant confusion over the manufacturing issues on the contract rates that you had and what it means for your 2020 outlook with